16th HIVHEP-pk presentations

Opening lecture: The Ebola Crisis – Prospects for Antiviral Treatment
Dr. S. Bavari
Invited lecture: HBV – What’s in the Pipeline?
Dr. S. Kottilil
Sensitivity of liver function classification systems for exposure changes
Dr. I. Younis
Evaluation of PK/PD Relationships between Ribavirin and Sustained Virologic Response in HCV-Genotype 3 Infected Subjects in the Sovaldi® Phase 3 Program
Dr. B. Kirby
Population viral kinetic modeling: SVR prediction in HCV GT-3 cirrhotic patients with 24 weeks of Daclatasvir + Sofosbuvir administration
Dr. T. Eley
Physiologically based pharmacokinetic model to predict drug-drug interaction in patients receiving antiretroviral and antineoplastic therapies
Dr. J. Moltó
Doravirine Efficacy Exposure-Response Analysis at Week 48 and Implications
Dr. K.L. Yee
Invited lecture: Nanoformulations – Enhancing drug exposure in cells
Dr. R. J. Ho
Invited lecture: Nanoformulations – an update from Janssen
Dr. H. Crauwels
Invited lecture: Nanoformulations – an update from GSK
Dr. W. Spreen
The pharmacokinetics of tenofovir and tenofovir diphosphate following administration of tenofovir alafenamide versus tenofovir disoproxil fumarate
Dr. J. Custodio
Microboosting of atazanavir 300 mg with 50 mg versus 100mg of ritonavir daily in HIV-infected patients
Dr. P. Giguère
Pharmacokinetics of GS-331007 Triphosphate in Red Blood Cells in HCV-infected Subjects Receiving Sofosbuvir plus Ribavirin in the SPARE trial
Dr. J. Rower
HIV-1 Attachment Inhibitor Prodrug BMS-663068: Exposure-Response Modeling in Predicting QTcF Interval Prolongation for Quantitative Dose Selection for the Phase 3 Program
Dr. I. Savant Landry
Prediction of Intracellular (IC) Tenofovir Diphosphate (TFV-DP) and Emtricitabine Triphosphate (FTC-TP) Concentrations Following Drug Intake Cessation
Dr. L. Dickinson
Disulfiram Reactivates Latent HIV Infection in a Dose-Dependent Manner
Dr. S. Lee
Case presentation: Recreational Drug Use
Dr. M. Boffito
Determining drug in Liver
Dr. A. Talal
Case presentation: Renal (AKD, CKD)
Dr. C. Wyatt
CYP3A5*1 Allele Not Associated with Lower Maraviroc Exposures in the Phase 2b/3 MERIT Study
Dr. M. Vourvahis
Pharmacokinetics (PK) of once-daily dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI) following drug cessation
Dr. E. Elliot
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus
Dr. K. Adkison
Model-Based Pediatric Dosing of Ritonavir-Boosted Darunavir: An Alternative to WHO Guidelines
Dr. H. Crauwels
Mini Lecture: The Clinical Pharmacology of HCV Drugs in Severe Liver Disease
Dr. J. Kiser
Company updates on the Clinical Pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: Abbvie
Dr. R. Menon
Company updates on the Clinical Pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: Merck
Dr. W. Yeh
Company updates on the Clinical Pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: Gilead
Dr. A. Mathias
Company updates on the Clinical Pharmacology and DDI profile of HCV drugs recently launched and in the pipeline: BMS
Dr. T. Eley
Yes - standpoint
Dr. D. Ripin
No - standpoint
Dr. R. Elion
FDA perspective
Dr. J. Murray
AbbVie sponsored Lecture
Current HCV Treatment Options in HIV Co-infected Patients
Dr. J. Rockstroh
Drug-Drug Interactions of Commonly Used Medications with Direct Acting Antiviral HCV Combination Therapy of Paritaprevir/r, Ombitasvir and Dasabuvir
Dr. A. Polepally
Coadministration of HCV Protease Inhibitor Grazoprevir With HCV NS5A Inhibitor Elbasvir Has No Effect On Pravastatin But Increases Rosuvastatin Exposure In Healthy Subjects
Dr. L. Caro
Readying HIV/HCV Coinfected Patients for HCV Treatment: Occurrence and Management of Antiviral Interactions
Dr. J. Langness
Sofosbuvir in haemodialysis: 400 mg daily or only the day of hemodialysis?
Dr. A. Desnoyer